A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Neeraj Agarwal; Arun Azad; Joan Carles; Simon Chowdhury; Bradley McGregor; Axel S. Merseburger; Stéphane Oudard; Fred Saad; Andrey Soares; Fawzi Benzaghou; Yannick Kerloeguen; Akiko Kimura; Nehal Mohamed; Ashok Panneerselvam; Fong Wang; Sumanta Pal

doi:10.2217/fon-2021-1096

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Neeraj Agarwal, Arun Azad, Joan Carles, Simon Chowdhury, Bradley McGregor, Axel S. Merseburger, Stéphane Oudard, Fred Saad, Andrey Soares, Fawzi Benzaghou, Yannick Kerloeguen, Akiko Kimura, Nehal Mohamed, Ashok Panneerselvam, Fong Wang, Sumanta Pal

33 Citations (Scopus)

Abstract

Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.

Original language	English
Journal	Future oncology (London, England)
Volume	18
Issue number	10
Pages (from-to)	1185-1198
Number of pages	14
ISSN	1479-6694
DOIs	https://doi.org/10.2217/fon-2021-1096
Publication status	Published - 01.03.2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-23 Reproductive Medicine, Urology
2.22-08 Pharmacy

Access to Document

10.2217/fon-2021-1096

Cite this

Agarwal, N., Azad, A., Carles, J., Chowdhury, S., McGregor, B., Merseburger, A. S., Oudard, S., Saad, F., Soares, A., Benzaghou, F., Kerloeguen, Y., Kimura, A., Mohamed, N., Panneerselvam, A., Wang, F., & Pal, S. (2022). A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future oncology (London, England), 18(10), 1185-1198. https://doi.org/10.2217/fon-2021-1096

@article{ca4614a2383242e58a04449fc17dac39,

title = "A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer",

abstract = "Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.",

author = "Neeraj Agarwal and Arun Azad and Joan Carles and Simon Chowdhury and Bradley McGregor and Merseburger, \{Axel S.\} and St{\'e}phane Oudard and Fred Saad and Andrey Soares and Fawzi Benzaghou and Yannick Kerloeguen and Akiko Kimura and Nehal Mohamed and Ashok Panneerselvam and Fong Wang and Sumanta Pal",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = mar,

day = "1",

doi = "10.2217/fon-2021-1096",

language = "English",

volume = "18",

pages = "1185--1198",

journal = "Future oncology (London, England)",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

Agarwal, N, Azad, A, Carles, J, Chowdhury, S, McGregor, B, Merseburger, AS, Oudard, S, Saad, F, Soares, A, Benzaghou, F, Kerloeguen, Y, Kimura, A, Mohamed, N, Panneerselvam, A, Wang, F & Pal, S 2022, 'A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer', Future oncology (London, England), vol. 18, no. 10, pp. 1185-1198. https://doi.org/10.2217/fon-2021-1096

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. / Agarwal, Neeraj; Azad, Arun; Carles, Joan et al.
In: Future oncology (London, England), Vol. 18, No. 10, 01.03.2022, p. 1185-1198.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

AU - Agarwal, Neeraj

AU - Azad, Arun

AU - Carles, Joan

AU - Chowdhury, Simon

AU - McGregor, Bradley

AU - Merseburger, Axel S.

AU - Oudard, Stéphane

AU - Saad, Fred

AU - Soares, Andrey

AU - Benzaghou, Fawzi

AU - Kerloeguen, Yannick

AU - Kimura, Akiko

AU - Mohamed, Nehal

AU - Panneerselvam, Ashok

AU - Wang, Fong

AU - Pal, Sumanta

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.

AB - Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.

UR - https://www.scopus.com/pages/publications/85126490290

UR - https://www.mendeley.com/catalogue/50c64964-d16d-3d61-b276-6b145a9f47f8/

U2 - 10.2217/fon-2021-1096

DO - 10.2217/fon-2021-1096

M3 - Journal articles

C2 - 35034502

AN - SCOPUS:85126490290

SN - 1479-6694

VL - 18

SP - 1185

EP - 1198

JO - Future oncology (London, England)

JF - Future oncology (London, England)

IS - 10

ER -